The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...
In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...
24/7 Wall St. on MSN
Trump’s Tariffs Led These 2 Companies To Invest Billions in The US
President Trump's reciprocal tariffs have led to unprecedented trillions in foreign investments into US manufacturing.
Scientists have discovered why males get dental disease more frequently and with greater severity than females, pinpointing ...
Centered on neurotrophic factor technology, Uni-Bio is pioneering innovative R&D in ENT regeneration, The Group is exploring novel solutions for reversing hearing loss and rebuilding olfactory ...
A University of Kentucky professor said the research has the potential to someday prevent millions of cases of Alzheimer’s in ...
8hon MSN
Off-label use of COVID-19 vaccines was once discouraged but has become common amid new guidelines
Following the federal government's changes to COVID-19 vaccine eligibility and recommendations in 2025, many people are ...
13hon MSN
Most people are happy to do their own hearing tests at home. Could it relieve pressure on the NHS?
Beyond relieving pressure on existing NHS services, home testing could offer patients greater choice, more convenience, ...
Kiwifruit might be small, but it packs a mighty nutritional punch that can transform your health. This fuzzy little ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for eye conditions, immune disorders, cancer, cardiovascular issues, infections, and rare diseases.
In this video from the American Academy of Ophthalmology meeting, Michael W. Stewart, MD, discusses 3-year data from the GALE study on geographic atrophy treatment with pegcetacoplan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback